BULL PHARMA: RISKS AND REALITIES

The rise of “shadowy pharma” companies presents some concerning risks to patient health, but the truth is often more complex than initial reports suggest. These entities , frequently operating outside conventional regulatory frameworks, may offer different therapies at lower costs, appealing to v